Aprovix AB

📍 Stockholm, Sweden🗓 Founded 2001👥 3 employees💰 Last funded Sep 2019
Medical Equipment Manufacturing🌐 qvintip.com
Website LinkedIn
Our vision is to contribute to a cervical cancer free world by driving the transition to self-sampling for HPV-testing. Aprovix is a medical technology company that was founded in 2001, based on an idea by Professor Erik Wilander of Uppsala. Aprovix’s business concept is to supply healthcare providers with a tailored, cost-effective and reliable self sampling process combined with HPV testing for early detection of pre-stages of cervix cancer. Qvintip® is CE marked and is registered with the Swedish Medical Products Agency as a class 1 medical device. Qvintip® is also ISO certified. Additional, Qvintip® is now available for private customers. Qvintip® is an at-home, easy-to-use, self-test solution for Human Papillomavirus (HPV) enabling early detection of risk for cervical cancer with the same accuracy as sampling performed at a clinic. The device allows women to collect a vaginal fluid sample for lab analysis in the comfort of her own home. For more information please visit www.qvintip.com
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
2001
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Sweden
2
Finland
1
Investor activity2013–2019 · investors recorded per year
2013120192
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Aprovix AB?
Aprovix AB has 3 investors on record on gritt.io.
When did Aprovix AB last raise funding?
The most recent investment in Aprovix AB recorded on gritt.io was in September 2019.
When was Aprovix AB founded?
Aprovix AB was founded in 2001.
What industry is Aprovix AB in?
Aprovix AB operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is Aprovix AB based?
Aprovix AB is headquartered in Stockholm, Sweden.